SCHEMBL25318410

SCHEMBL25318410

Cc1ccc(-c2ccc(OS(=O)(=O)C(F)(F)F)cc2)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.43
CCR5 P51681 1/20 0.43
CCR8 P51685 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2A6 P11509 1/20 0.43
PTGS2 P35354 6/20 0.42
RXFP1 Q9HBX9 1/20 0.38
GRIA2 P42262 1/20 0.38
PTGS1 P23219 1/20 0.38
KIF11 P52732 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
DGAT1 O75907 2/20 0.37
CXCR2 P25025 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
CHRNA7 P36544 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12254167 0.80 SMN1; SMN2 (0.56) DGAT1ALDH1A1
SCHEMBL7601977 0.80 NPC1 (0.52) PTGS2PTGS1CA1CA2ALDH1A1
SCHEMBL2750188 0.79 CA2 (0.57) CYP3A4KIF11CA1CA2CA9
SCHEMBL13471699 0.78 CCR1 (0.48) CCR1CCR5CCR8HDAC6CYP3A4
SCHEMBL26101909 0.78 KDM1A (0.39) GRIA2KIF11DGAT1
SCHEMBL6852624 0.77 CA1 (0.40) KIF11CA1CA2CA9CXCR2
Hydrogen Sulfide SCHEMBL6248782 0.77 CA2 (0.55) CYP3A4KIF11CA1CA2CA9
SCHEMBL23956245 0.77 PTGS2 (0.39) CYP3A4CYP2A6PTGS2GRIA2DGAT1
SCHEMBL23956253 0.77 PTGS2 (0.39) CYP3A4CYP2A6PTGS2GRIA2
Trifluoromethanesulfonic Acid SCHEMBL14655808 0.77 CYP3A4 (0.50) CCR1CCR5CCR8HDAC6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747244-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE Redx Pharma Limited (GB) 2026-05-27 EP disclosed
US-20250122173-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LTD (GB) 2025-04-17 US disclosed
WO-2025017306-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2025-01-23 WO disclosed
EP-4466071-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) Redx Pharma Limited (GB) 2024-11-27 EP disclosed
WO-2023139379-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) REDX PHARMA PLC (GB) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122173-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK1, ROCK2, RHOA CCR1 3459/4885CCR5 1979/4885CCR8 4345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.